DefiniGen specializes in the development of induced pluripotent stem cell (iPSC)-derived hepatocyte models, particularly their flagship product, Opti-HEP. These models are designed to provide highly functional and physiologically relevant systems for liver research, drug discovery, and toxicology screening. Opti-HEP hepatocytes are characterized by their ability to replicate key aspects of liver disease pathophysiology, making them suitable for a variety of applications, including efficacy and toxicity assessments of pharmaceutical compounds. The proprietary differentiation protocols employed by DefiniGen allow for the large-scale production of these hepatocytes, ensuring high purity and functionality, which are critical for generating reliable pre-clinical data.

In addition to hepatocytes, DefiniGen offers a diverse range of iPSC-derived cell products, including hepatic stellate cells and intestinal organoids, which further enhance their capabilities in disease modeling and drug discovery. Their platform supports the generation of disease-specific models, such as those for Wilson's Disease and Glycogen Storage Disease Type 1 Alpha, enabling researchers to study the underlying mechanisms of these conditions and evaluate potential therapeutic candidates. The company also emphasizes the importance of donor variability in their models, providing a broad panel of iPSC lines that reflect different demographics, which can aid in the stratification of clinical trials and improve the relevance of research outcomes.

United Kingdom

DefiniGEN are a Cambridge UK company providing highly functionalhuman cell productsincludingliver, pancreas, lung,and intestinal cells pluscustom servicesfor drug discovery and disease model generation.

DefiniGen

Company Details